ACTU Stock Forecast: Actuate Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.23
+5.28% on the day

The median 12-month analyst price target for Actuate Therapeutics, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$13.6M
Ticker Nerd rank
39/ 100
Median analyst target
$8.00
Analysts covering
3
Revenue$0.0
Operating income−$4.9M
Net income−$4.9M
Free cash flow−$4.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−20.9%
1M
−63.4%
YTD
−96.3%
1Y
−96.3%
From 52W high
−97.0%
From 52W low
+5.3%
$0.21
$7.63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Actuate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
39/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
83
Revisions
59
Accruals
53
Value
44
Issuance
39
Volatility
20
Quality
14
Momentum
2

Growth (83): Sales and profits are climbing, and climbing faster than before.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ACTU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACTU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26ACTUHigh $10.00Median $8.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$3.00
Low
$8.00
Median
$10.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Nov 2026HC Wainwright & Co.MaintainsBuy$15 → $10
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$15
30 July 2026Rodman & RenshawInitiatesBuy$6.00
18 May 2026HC Wainwright & Co.ReiteratesBuy$15
22 Apr 2026HC Wainwright & Co.ReiteratesBuy—
13 Apr 2026HC Wainwright & Co.MaintainsBuy—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
23 Sept 2025HC Wainwright & Co.ReiteratesBuy—
26 Aug 2025B. Riley SecuritiesInitiatesBuy—
18 Aug 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ACTU.

Market Radar

This page is one stock. Monday covers all of them.

ACTU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ACTU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Actuate Therapeutics, Inc. returned −96.3% against +6.9% for the S&P 500, dividends included.

ACTU vs S&P 500, last 12 monthsTotal return, rebased to 100
050100Jan 26Apr 26Jul 26Oct 26ACTUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACTU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.7×

Cheaper than 82% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−280.5%

Higher than 5% of US stocks

Return on assets
−213.4%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Actuate Therapeutics, Inc. has a market value of $13.6M and an enterprise value of $2.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$20.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.8M.

  • Shares outstanding: 24.0M.

  • Actuate Therapeutics, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ACTU and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACTUActuate Therapeutics, Inc.$13.6M39
NCELNewCelX Ltd.$13.6M4
BYSIBeyondSpring, Inc.$13.7M11
PLURPluri, Inc.$13.5M17
ESLAEstrella Immunopharma, Inc.$13.5M26
ABOSAcumen Pharmaceuticals, Inc.$13.5M42
CTXRCitius Pharmaceuticals, Inc.$14.0M34

Take a look at ACTU’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Actuate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ACTU

What is the ACTU stock price forecast for 2026-2027?

The median 12-month analyst price target for Actuate Therapeutics, Inc. is $8, with estimates ranging from $3 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACTU stock a buy right now?

Of the 3 analysts covering Actuate Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Actuate Therapeutics, Inc. 39 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACTU?

As at 21 Nov 2026, Actuate Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).

Will ACTU stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $8, and Ticker Nerd's factor model ranks Actuate Therapeutics, Inc. 39 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACTU stock forecast for 2030?

No analyst covering Actuate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACTU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $10 over the next 12 months.

How has ACTU stock performed over the past year?

Actuate Therapeutics, Inc. returned -96.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Actuate Therapeutics, Inc. do?

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. Its lead program centers on elraglusib, a small-molecule GSK-3 inhibitor being studied in clinical trials for advanced solid tumors and certain pediatric cancers.

Company

About Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. Its lead program centers on elraglusib, a small-molecule GSK-3 inhibitor being studied in clinical trials for advanced solid tumors and certain pediatric cancers. The company’s work is aimed at targeting cancer pathways involved in tumor growth, survival, and resistance to standard treatments. Actuate Therapeutics also explores applications in cancer types and related disease areas where conventional options remain limited, positioning it within the oncology drug development segment of the healthcare market. Headquartered in Fort Worth, Texas, Actuate Therapeutics concentrates on advancing investigational medicines through early and mid-stage development, with a business model built around translational research, clinical testing, and potential future commercialization of targeted therapies.

CEO Mr. Daniel M. Schmitt · 12 employees · United States · https://actuatetherapeutics.com